top of page


Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

Biopharma Funding Activity May 27th-31st 2024

Newly launched radioligand company and more funding events…

Want to get this list of recently funded companies and more data? Fill out a quote request to get more info (Quote Request Form)

FIG. 1. Recent Biotech Funding Activity.

Private Funding –


💸  Closed $33M Series B funding led by Two Sigma Ventures with RA Capital to advance the development of Fertilo.


💸  Raised additional €16M Series A funding led by Dawn Biopharma to strengthen ADC assets and advance its lead uPARAP program.


💸  Raised $13M seed funding co-led by Octopus Ventures and Redalpine to advance protein expression using AI-driven intronization technology.


💸  Raised €6.5M seed funding to fund a first-in-human trial of breakthrough topical ophthalmic inserts.

Radiomer Therapeutics

💸  Launched with undisclosed pre-seed funding to advance radioligand therapy platform. 

Post-IPO/Public Funding –


🏦  Announced ~$650M public offering to fund continued R&D of brensocatib and pre-commercial and, if approved, commercialization activities related to brensocatib. 


🏦  Closed $500M public offering. 


🏦  Announced their proposed $300M public offering and intends to use the proceeds from the offering to advance the clinical development of its product candidates, among others.

BioNano Genomics

🏦  Raised $18M in private placement to eliminate debt and advance optical genome mapping technology. 


🏦  Announced pricing of $9.3M direct offering to be used for sales and marketing, working capital, and general corporate purposes. ---

Article History:

RF, DV, DG (06/04/24)

This article is not investment or legal advice.


bottom of page